tanzania times : Latest News and In-depth Analysis
Contact Us
Search

Energy

tanzania times : Latest News and In-depth Analysis
HomeEnergy
Energy

Mar 18, 2025

GoEnhanceAI Releases Video-to-Video V4 with 30+ Styles and Public API Access

SHERIDAN,Wyo.,March 17,2025-- GoEnhanceAI,a leading AI video generation platform,has launched its fourth-generation video-to-video technology,marking a major leap forward in AI-powered video creation.

All News

Energy

TECNO CAMON 40 Pro 5G Achieves 138 DXOMARK Camera Score, with the Best Photo Performance for Smartphones Under $600

HONG KONG,March 5,2025-- The TECNO CAMON 40 Pro 5G has achieved remarkable acclaim in evaluations conducted by the esteemed imaging authority,DXOMARK,with a remarkable 138 DXOMARK camera score. Its p

Mar 5, 2025

Energy

CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland

CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small,medium,and large peptide manufacturing facilities across Europe and the US.

Mar 5, 2025

Safeguarding Your Assets: ATFX's Commitment to Trust and Security

HONG KONG,Feb. 28,2025-- ATFX,a leading CFD broker,has always placed client fund protectionat the core of its operations. Recognizing the rise in cyberattacks targeting brokers,ATFX has implemented ad

Mar 3, 2025

Energy

A*STAR And MojiaBio To Develop Next-gen Sustainable Biomanufacturing Platform In Singapore

SINGAPORE,Feb. 28,2025-- This initiative aims to produce eco-friendly bio-based molecules from low-cost,eco-friendly sources. Key benefits include:

Mar 3, 2025

Energy

LubTop2024 and ApexTire2024: The 'Oscars' of the Automotive Aftermarket Unite to Chart a New Path

SHENZHEN,China,Feb. 28,2025-- In an era of rapid transformation,where the global automotive industry is accelerating towards intelligent and green technologies,what challenges and opportunities lie ah

Mar 3, 2025

Energy

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases

Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis

Mar 3, 2025

1 ... 44 45 46 47 48 49 50 ... 102